Eval. of Safety and Effectiveness of the FMwand Ferromagnetic Surgical System During Total Mesorectal Excision Surgery

Inclusion Criteria:

* Confirmed rectal cancer to the lower two-thirds of the rectum (higher and T2 N0 or N+)
* Amenable for standard surgery procedures using electrocautery, argon beam, lasers or other conventional tissue removal modalities
* ECOG status ≤ 2
* Life expectancy \>3 months
* Age ≥ 18 years old
* Age ≤ 80 years old
* Ability to provide written informed consent and HIPAA forms prior to admission to this study
* Willingness to meet all of the expected requirements of this clinical protocol

Exclusion Criteria:

* Patient with metastasis
* History of radiotherapy or chemotherapy for the treatment of rectal cancer
* Uremia - BUN\>40
* Hemodialysis
* Existing urinary or fecal incontinence
* Pregnant or lactating
* Previously diagnosed coagulopathy or bleeding diathesis
* Currently, or within the previous 10 days prior to surgery, taking any medications that would produce bleeding diathesis including but not limited to, Plavix, warfarin, NSAIDs, clopidogrel, ticlopidine or valproic acid
* History of significant cardiac disorders that would necessitate special fluid management protocols
* History of acute myocardial infarction and/or acute angina
* INR \>1.4 in the 24 hours prior to surgery
* PTT \>40 in the 24 hours prior to surgery
* Platelet count \<100K in the 24 hours prior to surgery